- Published on
Ophthalmology – Crohn’s Disease & Ulcerative Colitis (IBD)
Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic inflammatory condition of the gastrointestinal tract with important extra-intestinal manifestations, including the eye. Ocular involvement can affect nearly all layers of the eye, ranging from mild surface inflammation to severe vision-threatening disease. The most common ophthalmic manifestations include episcleritis, anterior uveitis, scleritis, keratitis, and retinal vasculitis. Although ocular disease is not usually the presenting feature of IBD, it occurs in 3.5–11.8% of patients, with Crohn’s disease generally having more ocular involvement than ulcerative colitis.
The underlying mechanism involves a systemic inflammatory response driven by immune dysregulation in genetically predisposed individuals. This results in infiltration of inflammatory mediators into ocular tissues, leading to edema, tissue damage, and dysfunction. Genetic associations such as HLA-B27 significantly increase the risk of ocular inflammation, particularly acute anterior uveitis. Other associated HLA types include HLA-B58 and HLA-DRB1 variants.
Clinically, symptoms depend on the structure involved. Episcleritis presents with mild redness and irritation without vision loss and often correlates with intestinal disease activity. Anterior uveitis causes pain, photophobia, and blurred vision and may occur independently of bowel disease activity. Scleritis is more severe, presenting with deep, boring pain and tenderness and can threaten vision. Keratitis produces sharp pain and photophobia, while posterior uveitis or retinal vasculitis may lead to blurred vision and retinal complications such as macular edema.
On examination, slit-lamp findings vary by condition. Episcleritis shows superficial redness that blanches with phenylephrine, whereas scleritis shows deeper inflammation that does not blanch and is often tender. Anterior uveitis demonstrates ciliary flush with cells and flare in the anterior chamber. Posterior involvement may reveal vitreous inflammation, vascular sheathing, or macular edema, often requiring imaging such as fluorescein angiography. A B-scan ultrasound may show a characteristic T-sign in posterior scleritis.
Management depends on severity. Episcleritis is usually mild and treated with artificial tears or topical steroids if needed. Anterior uveitis requires intensive topical steroids and cycloplegics. Scleritis often needs systemic therapy such as oral NSAIDs or corticosteroids. More severe or refractory cases—including keratitis and posterior uveitis—may require systemic immunosuppressive therapy such as methotrexate, azathioprine, or anti-TNF agents. Close collaboration with gastroenterology is important, as control of systemic IBD activity helps reduce ocular inflammation.
Follow-up is essential until inflammation resolves. Patients on long-term corticosteroids must be monitored for glaucoma and cataracts, while ongoing inflammation can lead to complications such as macular edema or, rarely, phthisis bulbi. Overall prognosis is generally good, as most patients respond well to treatment, especially when diagnosed early and managed appropriately.
Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic inflammatory condition of the gastrointestinal tract with important extra-intestinal manifestations, including the eye. Ocular involvement can affect nearly all layers of the eye, ranging from mild surface inflammation to severe vision-threatening disease. The most common ophthalmic manifestations include episcleritis, anterior uveitis, scleritis, keratitis, and retinal vasculitis. Although ocular disease is not usually the presenting feature of IBD, it occurs in 3.5–11.8% of patients, with Crohn’s disease generally having more ocular involvement than ulcerative colitis.
The underlying mechanism involves a systemic inflammatory response driven by immune dysregulation in genetically predisposed individuals. This results in infiltration of inflammatory mediators into ocular tissues, leading to edema, tissue damage, and dysfunction. Genetic associations such as HLA-B27 significantly increase the risk of ocular inflammation, particularly acute anterior uveitis. Other associated HLA types include HLA-B58 and HLA-DRB1 variants.
Clinically, symptoms depend on the structure involved. Episcleritis presents with mild redness and irritation without vision loss and often correlates with intestinal disease activity. Anterior uveitis causes pain, photophobia, and blurred vision and may occur independently of bowel disease activity. Scleritis is more severe, presenting with deep, boring pain and tenderness and can threaten vision. Keratitis produces sharp pain and photophobia, while posterior uveitis or retinal vasculitis may lead to blurred vision and retinal complications such as macular edema.
On examination, slit-lamp findings vary by condition. Episcleritis shows superficial redness that blanches with phenylephrine, whereas scleritis shows deeper inflammation that does not blanch and is often tender. Anterior uveitis demonstrates ciliary flush with cells and flare in the anterior chamber. Posterior involvement may reveal vitreous inflammation, vascular sheathing, or macular edema, often requiring imaging such as fluorescein angiography. A B-scan ultrasound may show a characteristic T-sign in posterior scleritis.
Management depends on severity. Episcleritis is usually mild and treated with artificial tears or topical steroids if needed. Anterior uveitis requires intensive topical steroids and cycloplegics. Scleritis often needs systemic therapy such as oral NSAIDs or corticosteroids. More severe or refractory cases—including keratitis and posterior uveitis—may require systemic immunosuppressive therapy such as methotrexate, azathioprine, or anti-TNF agents. Close collaboration with gastroenterology is important, as control of systemic IBD activity helps reduce ocular inflammation.
Follow-up is essential until inflammation resolves. Patients on long-term corticosteroids must be monitored for glaucoma and cataracts, while ongoing inflammation can lead to complications such as macular edema or, rarely, phthisis bulbi. Overall prognosis is generally good, as most patients respond well to treatment, especially when diagnosed early and managed appropriately.
0 Comments
